More information: Eleri A. Ashworth et al, Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo, Nature Communications (2024).

BiomX has dosed the first subject in the randomised Phase IIb trial of the company’s fixed multi-phage therapy, BX004, to ...

Pseudomonas aeruginosa is a type of bacteria commonly found in the environment, such as soil, water, and plants, and as part of bacteria residing in humans. It is both a pathogen and opportunistic ...

Adaptive responses of Pseudomonas aeruginosa to treatment with antibiotics. Antimicrobial Agents and Chemotherapy, 2021; DOI: 10.1128/AAC.00878-21 ...

BiomX Inc. (AMEX:PHGE) saw its stock jump 60% after announcing the commencement of patient dosing in its Phase 2b clinical trial evaluating BX004 for cystic fibrosis patients suffering from chronic ...

BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating that its phage cocktail BX004 ...

Pseudomonas aeruginosa is a human pathogen which can cause life-threatening illness, especially in people who have a depleted immune system. One of the ways P. aeruginosa causes infection is ...

Pictured: an artist's impression of Pseudomonas aeruginosa bacteria, main, and plastic medical equipment, inset. ivan68 / quantic69/iStock / Getty Images Plus ...

Pseudomonas aeruginosa is an opportunistic pathogen responsible for morbidity and mortality in humans, animals, and plants. This bacterium has been regarded to be widely present in terrestrial and ...

They occur widely in nature. The type species Pseudomonas aeruginosa (Pseudomonas pyocyanea, Bacillus pyocyaneus) is pathogenic for man. It grows readily on all ordinary culture mediums.